Assessment of Effect of Rapastinel on Driving Performance

Study Identifier
RAP-PK-18
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Other
  • Study Drug
  • Rapastinel
  • Alprazolam
  • Ketamine
  • Rapastinel Matched Placebo
  • Alprazolam Matched Placebo
  • Ketamine Matched Placebo
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    21 - 65 Years

    Protocol Summary

    Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.

    Study Locations

    Location
    Status
    Location
    Collaborative Neuroscience Network
    San Clemente, California, United States, 92673
    Status
    Not applicable
    Location
    Algorithme Pharma
    Aurora, Ontario, Canada, L4G 0A5
    Status
    Not applicable